Cingulate Inc. (CINGW) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Kansas City, KS, 美国. 现任CEO为 Shane J. Schaffer.
CINGW 拥有 IPO日期为 2021-12-08, 13 名全职员工, 在 NASDAQ Capital Marke, 市值为 $141.82K.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
